The use of mucoadhesive polymers in ocular drug delivery

Advanced Drug Delivery Reviews

Volumn 57, Issue 11, 2005, Pages 1595-1639

  Ludwig, Annick ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Hydrogel; In situ gelling system; Insert; Minitablet; Mucins; Mucoadhesion; Particulate systems; Viscous solution

Indexed keywords

ADHESIVES; BIOCHEMISTRY; COMPLEXATION; DISEASES; HYDROGELS; POLYMERS; SOLUTIONS;

IN SITU GELLING SYSTEM; INSERT; MINITABLETS; MUCINS; MUCOADHESION; PARTICULATE SYSTEM; VISCOUS SOLUTIONS;

DRUG PRODUCTS;

ACRYLIC ACID DERIVATIVE; ALGINIC ACID; CARBOMER; CARBOXYMETHYLCELLULOSE; CARTEOLOL; CELLULOSE DERIVATIVE; CHITOSAN; EUDRAGIT; GELLAN; GELRITE; HYALURONIC ACID; HYDROCORTISONE; HYDROXYPROPYLMETHYLCELLULOSE; LIPOSOME; MACROGOL; METHYLCELLULOSE; MICROSPHERE; MUCIN; NANOPARTICLE; OFLOXACIN; PECTIN; PILOCARPINE; POLOXAMER; POLYACRYLIC ACID; POLYMER; POLYSACCHARIDE; POLYVINYL ALCOHOL; POVIDONE; SCLEROGLUCAN; TIMOLOL; TIMOLOL MALEATE; TOBRAMYCIN; TROPICAMIDE; UNINDEXED DRUG; XANTHAN;

ANATOMY; BIOCHEMISTRY; DRAIN; DRUG DELIVERY SYSTEM; DRUG RELEASE; EYE DISEASE; HUMAN; HYDROGEL; LIQUID; MEDICAL TECHNOLOGY; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SOLID; TABLET FORMULATION; TEAR FILM; VISCOSITY;

ANIMALS; DOSAGE FORMS; DRUG DELIVERY SYSTEMS; EXCIPIENTS; EYE; HUMANS; MUCOUS MEMBRANE; OCULAR PHYSIOLOGY; SOLUTIONS; TEARS;

EID: 26644437438     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2005.07.005     Document Type: Review

References (341)

1. V.H.L. Lee, and J.R. Robinson Review: topical ocular drug delivery: recent developments and future challenges J. Ocul. Pharmacol. 2 1986 67 108
2. L. Salminen Review: systemic absorption of topically applied ocular drugs in humans J. Ocul. Pharmacol. 6 1990 243 249
3. C. Baudouin Side effects of antiglaucomatous drugs on the ocular surface Curr. Opin. Ophthalmol. 7 1996 80 86
4. A. Topalkara, C. Güler, D.S. Arici, and M.K. Arici Adverse effects of topical antiglaucoma drugs on the ocular surface Clin. Exp. Ophthalmol. 28 2000 113 117
5. K.C. Swan The use of methyl cellulose in ophthalmology Arch. Ophthalmol. 33 1945 378 380
6. A. Ludwig, and M. Van Ooteghem Influence of viscolysers on the residence of ophthalmic solutions evaluated by slit lamp fluorophotometry S.T.P. Pharma Sci. 2 1992 81 87
7. M.F. Saettone, B. Giannaccini, A. Teneggi, P. Savigni, and N. Tellini Vehicle effects on ophthalmic bioavailability: the influence of different polymers on the activity of pilocarpine in rabbit and man J. Pharm. Pharmacol. 34 1982 464 466
8. M.F. Saettone, B. Giannaccini, F. Barattini, and N. Tellini The validity of rabbits for investigations on ophthalmic vehicles: a comparison of four different vehicles containing tropicamide in humans and rabbits Pharm. Acta Helv. 57 1982 47 55
9. I. Zaki, P. Fitzgerald, J.G. Hardy, and C.G. Wilson A comparison of the effects of viscosity on the precorneal residence of solutions in rabbit and man J. Pharm. Pharmacol. 38 1986 463 466
10. J.L. Greaves, and C.G. Wilson Treatment of diseases of the eye with mucoadhesive delivery systems Adv. Drug Deliv. Rev. 11 1993 349 383
11. J.C. Robinson Ocular anatomy and physiology relevant to ocular drug delivery A.K. Mitra Ophthalmic Drug Delivery Systems 1993 Marcel Dekker New York 29 57
12. O. Dudinski, B.C. Finnin, and B.L. Reed Acceptability of thickened eye drops to human subjects Curr. Ther. Res. 33 1983 322 337
13. M.B. Sintzel, S.F. Bernatchez, C. Tabatabay, and R. Gurny Biomaterials in ophthalmic drug delivery Eur. J. Pharm. Biopharm. 42 1996 358 374
14. H. Ibrahim, C. Bindschaedler, E. Doelker, P. Buri, and R. Gurny Concept and development of ophthalmic pseudo-lattices triggered by pH Int. J. Pharm. 77 1991 211 219
15. S.C. Miller, and M.D. Donovan Effect of poloxamer 407 gel on the miotic activity of pilocarpine nitrate in rabbits Int. J. Pharm. 12 1982 147 152
16. A. Rozier, C. Mazuel, J. Grove, and B. Plazonnet Gelrite®: a novel, ion-activated in-situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol Int. J. Pharm. 57 1989 163 168
17. J.R. Robinson, and G.M. Mlynek Bioadhesive and phase-change polymers for ocular drug delivery Adv. Drug Deliv. Rev. 16 1995 45 50
18. H.-W. Hui, and J.R. Robinson Ocular drug delivery of progesterone using a bioadhesive polymer Int. J. Pharm. 26 1985 203 213
19. J.K. Vasir, K. Tambwekar, and S. Garg Bioadhesive microspheres as a controlled drug delivery system Int. J. Pharm. 255 2003 13 32
20. J.R. Robinson Ocular drug delivery. Mechanism(s) of corneal transport and mucoadhesive delivery systems S.T.P. Pharma 5 1989 839 846
21. C.A. Le Bourlais, L. Treupel-Acar, C.T. Rhodes, P.A. Sado, and R. Leverge New ophthalmic drug delivery systems Drug Dev. Ind. Pharm. 21 1995 19 59
22. M. Calonge The treatment of dry eye Surv. Ophthalmol. 45 Suppl. 2 2001 S227 S239
23. R. Krisnamoorthy, and A.K. Mitra Mucoadhesive polymers in ocular drug delivery A.K. Mitra Ophthalmic Drug Delivery Systems 1993 Marcel Dekker New York 199 221
24. H. Sasaki, K. Yamamura, K. Nishida, J. Nakamura, and M. Ichikawa Delivery of drugs to the eye by topical application Prog. Retin. Eye Res. 15 1996 583 620
25. C. Le Bourlais, L. Acar, H. Zia, P.A. Sado, T. Needham, and R. Leverge Ophthalmic drug delivery systems-recent advances Prog. Retin. Eye Res. 17 1998 33 58
26. M.F. Saettone, S. Burgalassi, and P. Chetoni Ocular bioadhesive drug delivery systems E. Mathiowitz D.E. Chickering C.-M. Lehr Bioadhesive Drug Delivery Systems. Fundamentals, Novel Approaches and Development 1999 Marcel Dekker, Inc. New York 601 640
27. I.P. Kaur, and R. Smitha Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmic drug delivery Drug Dev. Ind. Pharm. 28 2002 353 369
28. M.M. Van Ooteghem Factors influencing the retention of ophthalmic solutions on the eye surface M.F. Saettone M. Bucci P. Speiser Ophthalmic Drug Delivery. Biopharmaceutical, Technological and Clinical Aspects Fidia Research Series vol. 11 1987 Livinia Press Padova 7 17
29. Y. Ban, A. Dota, L.J. Cooper, N.J. Fullwood, T. Nakamura, M. Tsuzuki, C. Mochida, and S. Kinoshita Tight junction-related protein expression and distribution in human corneal epithelium Exp. Eye Res. 76 2003 663 669
30. K. Järvinen, T. Järvinen, and A. Urtti Ocular absorption following topical delivery Adv. Drug Deliv. Rev. 16 1995 3 19
31. P. Versura, F. Bonvicini, R. Caramazza, and R. Laschi Scanning electron microscopy of normal corneal epithelium obtained by scraping-off in vivo Acta Ophthalmol. (Copenh.) 63 1985 361 365
32. A.J.W. Huang, S.C.G. Tseng, and K.R. Kenyon Paracellular permeability of corneal and conjunctival epithelia Invest. Ophthalmol. Visual Sci. 30 1989 684 689
33. A.C.H. Yeo, A. Carkeet, L.G. Carney, and M.K.H. Yap Relationship between goblet cell density and tear function tests Ophthalmic Physiol. Opt. 23 2003 87 94
34. B.A. Nichols, M.L. Chiappino, and C.R. Dawson Demonstration of the mucus layer of the tear film by electron microscopy Invest. Ophthalmol. Visual Sci. 26 1985 464 473
35. M.I. Roat, M. Ohji, L.E. Hunt, and R.A. Thoft Conjunctival epithelial cell hypermitosis, goblet cell hyperplasia in atopic keratoconjunctivitis Am. J. Ophthalmol. 116 1993 456 463
36. K.S. Kunert, A.M. Keane-Myers, S. Spurr-Michaud, A.S. Tisdale, and I.K. Gipson Alteration in goblet cell numbers and mucin gene expression in a mouse model of allergic conjunctivitis Invest. Ophthalmol. Visual Sci. 42 2001 2483 2489
37. P.J. Pisella, E. Lala, V. Parier, F. Brignole, and C. Baudouin Retentissement conjonctival des conservateurs: étude comparative de collyres bêta-bloquants conservés et non conservés chez des patients glaucomateux J. Fr. Ophtalmol. 26 2003 675 679
38. S. Kinoshita, T.C. Kiorpes, J. Friend, and R.A. Thoft Goblet cell density in ocular surface disease. A better indicator than tear mucin Arch. Ophthalmol. 101 1983 1284 1287
39. P.N. Dilly On the nature and the role of the subsurface vesicles in the outer epithelial cells of the conjunctiva Br. J. Ophthalmol. 69 1985 477 481
40. J.V. Greiner, T.A. Weidman, D.R. Korb, and M.R. Allansmith Histochemical analysis of secretory vesicles in non-goblet conjunctival epithelial cells Acta Ophthalmol. (Copenh.) 63 1985 89 92
41. G. Langer, W. Jagla, W. Behrens-Baumann, S. Walter, and W. Hoffmann Secretory peptides TFF1 and TFF3 synthesized in human conjunctival goblet cells Invest. Ophthalmol. Visual Sci. 40 1999 2220 2224
42. M. Ayub, A.B. Thale, J. Hedderich, B.N. Tillmann, and F.P. Paulsen The cavernous body of the efferent tear ducts contributes to regulation of tear outflow Invest. Ophthalmol. Visual Sci. 44 2003 4900 4907
43. J. Murube, L. Murube, and A. Murube Origin and types of emotional tearing Eur. J. Ophthalmol. 9 1999 77 84
44. S. Mishima, A. Gasset, D. Klyce, and J.L. Baum Determination of tear volume and tear flow Invest. Ophthalmol. Visual Sci. 5 1966 264 276
45. K. Tsubota Tear dynamics and dry eye Prog. Retin. Eye Res. 17 1998 565 596
46. J.P. Diamond Systemic adverse effects of topical ophthalmic agents. Implications for older patients Drugs Aging 11 1997 352 360
47. O. Elibol, T. Alçelik, and N. Yüksel The influence of drop size of cyclopentolate, phenylephrine and tropicamide on pupil dilatation and systemic side effects in infants Acta Ophthalmol. Scand. 75 1997 178 180
48. F.P. Paulsen, M. Föge, A.B. Thale, B.N. Tillmann, and R. Mentlein Animal model for the absorption of lipophilic substances from tear fluid by the epithelium of the nasolacrimal ducts Invest. Ophthalmol. Visual Sci. 43 2002 3137 3143
49. P.L. Lama Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment Am. J. Ophthalmol. 134 2002 749 760
50. V. Bayens, and R. Gurny Chemical and physical parameters of tears relevant for the design of ocular drug delivery formulations Pharm. Acta Helv. 72 1997 191 202
51. P.E. King-Smith, B.A. Fink, N. Fogt, K.K. Nichols, R.M. Hill, and G.S. Wilson The thickness of the human precorneal tear film: evidence from reflection spectra Invest. Ophthalmol. Visual Sci. 41 2000 3348 3359
52. W.D. Mathers, J.A. Lane, J.E. Sutphin, and M.B. Zimmerman Model for ocular tear film function Cornea 15 1996 110 119
53. S.C.G. Tseng, and K. Tsubota Important concepts for treating ocular surface and tear disorders Am. J. Ophthalmol. 124 1997 825 835
54. N.J. Van Haeringen Clinical biochemistry of tears Surv. Ophthalmol. 5 1981 84 96
55. B. Nagyova, and J.M. Tiffany Components responsible for the surface tension of human tears Curr. Eye Res. 19 1999 4 11
56. J.M. Tiffany Tears in health and disease Eye 17 2003 1 4
57. M. Tei, S.J. Spurr-Michaud, A.S. Tisdale, and I.K. Gipson Vitamin A deficiency alters the expression of mucin genes by the rat ocular surface epithelium Invest. Ophthalmol. Visual Sci. 41 2000 82 88
58. J.C. Pandit, B. Nagyova, A.J. Bron, and J.M. Tiffany Physical properties of stimulated and unstimulated tears Exp. Eye Res. 68 1999 247 253
59. I.K. Gipson, M. Yankauckas, S.J. Spurr-Michaud, A.S. Tisdale, and W. Rinehart Characteristics of a glycoprotein in the ocular surface glycocalyx Invest. Ophthalmol. Visual Sci. 33 1992 218 227
60. J.I. Prydal, P. Artal, H. Woon, and F.W. Campell Study of the human precorneal tear film thickness and structure using laser interferometry Invest. Ophthalmol. Visual Sci. 33 1992 2006 2011
61. H.-B. Chen, S. Yamabayashi, B. Ou, Y. Tanaka, S. Ohno, and S. Tsukahara Structure and composition of rat precorneal tear film. A study by an in vitro cryofixation Invest. Ophthalmol. Visual Sci. 38 1997 381 387
62. H.-B. Chen, S. Yamabayashi, B. Ou, Y. Tanaka, S. Ohno, and S. Tsukahara Histological study on rat tear film and ocular surface epithelial cells Curr. Eye Res. 17 1998 642 649
63. K. Khanvilkar, M.D. Donovan, and D.R. Flanagan Drug transfer through mucus Adv. Drug Deliv. Rev. 48 2001 173 193
64. T.J. McMaster, M. Berry, A.P. Corfield, and M.J. Miles Atomic force microscopy of the submolecular architecture of hydrated ocular mucins Biophys. J. 77 1999 533 541
65. P. Argüeso, and I.K. Gipson Epithelial mucins of the ocular surface: structure, biosynthesis and function Exp. Eye Res. 73 2001 281 289
66. Y. Danjo, L.D. Hazlett, and I.K. Gipson C57BL/6 mice lacking MUC1 show no ocular surface phenotype Invest. Ophthalmol. Visual Sci. 41 2000 4080 4084
67. R.B. Ellingham, M. Berry, D. Stevenson, and A.P. Corfield Secreted human conjunctival mucus contains MUC5AC glycoforms Glyobiology 9 1999 1181 1189
68. I.K. Gipson, and T. Inatomi Mucin genes expressed by the ocular surface epithelium Prog. Retin. Eye Res. 16 1997 81 98
69. C. Lange, J. Fernandez, D. Shim, S. Spurr-Michaud, A. Tisdale, and I.K. Gipson Mucin gene expression is not regulated by estrogen and/or progesterone in the ocular surface epithelia of mice Exp. Eye Res. 77 2003 59 68
70. P. Argüeso, S.J. Spurr-Michaud, C.L. Russo, A. Tisdale, and I.K. Gipson MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope Invest. Ophthalmol. Visual Sci. 44 2003 2487 2495
71. M.M. Jumblatt, R.W. McKenzie, P.S. Steele, C.G. Emberts, and J.E. Jumblatt MUC7 expression in the human lacrimal gland and conjunctiva Cornea 22 2003 41 45
72. T. Inatomi, S. Spurr-Michaud, A.S. Tisdale, and I.K. Gipson Human corneal and conjunctival epithelia express MUC1 Invest. Ophthalmol. Visual Sci. 36 1995 1818 1827
73. M. Berry, R.B. Ellingham, and A.P. Corfield Membrane-associated mucins in normal human conjunctiva Invest. Ophthalmol. Visual Sci. 41 2000 398 403
74. S.C. Pflugfelder, Z. Liu, D. Monroy, D.-Q. Li, M.E. Carvajal, S.A. Price-Schiavi, N. Idris, A. Solomon, A. Perez, and K.L. Carraway Detection of sialomucin complex (MUC4) in human ocular surface epithelium and tear fluid Invest. Ophthalmol. Visual Sci. 41 2000 1316 1326
75. A.C.H. Yeo, A. Carkeet, L.G. Carney, and M.K.H. Yap Relationship between goblet cell density and tear function tests Ophthalmic Physiol. Opt. 23 2003 87 94
76. T. Inatomi, S. Spurr-Michaud, A.S. Tisdale, Q. Zhan, S.T. Feldman, and I.K. Gipson Expression of secretory mucin genes by human conjunctival epithelia Invest. Ophthalmol. Visual Sci. 37 1996 1684 1692
77. M.M. Jumblatt, R.W. McKenzie, and J.E. Jumblatt MUC5AC mucin is a component of the human precorneal tear film Invest. Ophthalmol. Visual Sci. 40 1999 43 49
78. R. Kuver, J.H. Klinkspoor, W.R. Osborne, and S.P. Lee Mucous granule excytosis and CFTR expression in gallbladder epithelium Glycobiology 10 2000 149 157
79. G. Forstner Signal transduction, packaging and secretion of mucin Annu. Rev. Physiol. 57 1995 585 605
80. J.P. Gilbard Human tear film electrolyte concentration in health and dry-eye disease Int. Ophthalmol. Clin. 34 1994 27 36
81. H.B. Paz, A.S. Tisdale, Y. Danjo, S.J. Spurr-Michaud, P. Argüeso, and I.K. Gipson The role of calcium in mucin packaging within goblet cells Exp. Eye Res. 77 2003 69 75
82. P. Argüeso, M. Balaram, S. Spurr-Michaud, H.T. Keutmann, M.R. Dana, and I.K. Gipson Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sjögren syndrome Invest. Ophthalmol. Visual Sci. 43 2002 1004 1011
83. M. Berry, A. Harris, R. Lumb, and K. Powell Commensal ocular bacteria degrade mucins Br. J. Ophthalmol. 86 2002 1412 1416
84. L.P. Aristoteli, and M.D.P. Willcox Adhesion of Pseudomonas aeruginosa ocular isolates to mucin Clin. Exp. Ophthalmol. 29 2001 143 146
85. L.P. Aristoteli, B. Bojarski, and M.D.P. Willcox Isolation of conjunctival mucin and differential interaction with Pseudomonas aeruginosa strains of varied pathogenic potential Exp. Eye Res. 77 2003 699 710
86. 2 Invest. Ophthalmol. Visual Sci. 31 1990 138 146
87. Y. Diebold, J.D. Rios, R.R. Hodges, I. Rawe, and D.A. Dartt Presence of nerves and their receptors in mouse and human conjunctival goblet cells Invest. Ophthalmol. Visual Sci. 42 2001 2270 2282
88. C. Baudouin Pathology of dry eye Surv. Ophthalmol. 45 Suppl. 2 2001 211 220
89. J.E. Jumblatt, and M.M. Jumblatt Regulation of ocular mucin secretion by P2Y2 nucleotide receptors in rabbit and human conjunctiva Exp. Eye Res. 67 1998 341 346
90. B.R. Yerxa Therapeutic use of nucleotides in respiratory and ophthalmic diseases Drug Dev. Res. 52 2001 196 201
91. M.V. Mundasad, G.D. Novack, V.E. Allgood, R.M. Evans, J.C. Gorden, and B.R. Yerxa Ocular safety of INS365 ophthalmic solution: a P2Y2 agonist in healthy subjects J. Ocul. Pharmacol. Ther. 17 2001 173 179
92. 2 receptors elicits PAS-positive glycoprotein secretion from rabbit conjunctival goblet cells in vivo J. Ocul. Pharmacol. Ther. 19 2003 345 352
93. J. Pintor, A. Peral, T. Pelaez, G. Carracedo, A. Bautista, and C.H.V. Hoyle Nucleotides and dinucleotides in ocular physiology: new possibilities of nucleotides as therapeutic agents in the eye Drug Dev. Res. 59 2003 136 145
94. J.E. Jumblatt, L.T. Cunningham, Y. Li, and M.M. Jumblatt Characterization of human ocular secretion mediated by 15(S)-HETE Cornea 21 2002 818 824
95. Y. Danjo, H. Watanabe, A. Tisdale, M. George, T. Tsumura, M.B. Abelson, and I.K. Gipson Alteration of mucin in human conjunctival epithelia in dry eye Invest. Ophthalmol. Visual Sci. 39 1998 2602 2609
96. O.D. Schein, J.M. Tielsh, B. Munoz, K. Bandeen-Roche, and S. West Relation between signs and symptoms of dry eye in the elderly. A population-based perspective Ophthalmology 104 1997 1395 1401
97. C.A. McCarty, A.K. Bansal, P.M. Livingston, Y.L. Stanislavsky, and H.R. Taylor The epidemiology of dry eye in Melbourne, Australia Ophthalmology 105 1998 1114 1119
98. A. Tomlinson, E.I. Pearce, P.A. Simmons, and K. Blades Effect of oral contraceptives on tear physiology Ophthalmic Physiol. Opt. 21 2001 9 16
99. D.A. Schaumberg, J.E. Buring, D.A. Sullivan, and M.R. Dana Hormone replacement therapy and dry eye syndrome JAMA 286 2001 2114 2119
100. A. Pelit, T. Bagis, F. Kayaselcuk, D. Dursum, Y. Akova, and P. Aydin Tear function tests and conjunctival impression cytology before and after hormone replacement therapy in postmenopausal women Eur. J. Ophthalmol. 13 2003 337 342
101. J.W. Lee, J.H. Park, and J.R. Robinson Bioadhesive-based dosage forms: the next generation J. Pharm. Sci. 89 2000 850 866
102. A.G. Mikos, and N.A. Peppas Systems for controlled drug delivery of drugs: V. Bioadhesive systems S.T.P. Pharma Sci. 2 1986 705 716
103. M.E. Imam, M. Hornof, C. Valenta, G. Reznicek, and A. Bernkop-Schnuerch Evidence for the interpenetration of mucoadhesive polymers into the mucous gel layer S.T.P. Pharma Sci. 13 2003 171 176
104. S.A. Mortazavi, and J.D. Smart Factors influencing gel-strengthening at the mucoadhesive-mucus interface J. Pharm. Pharmacol. 46 1993 86 90
105. F. Madsen, K. Eberth, and J.D. Smart A rheological examination of the mucoadhesive/mucus interaction: the effect of mucoadhesive type and concentration J. Control. Release 50 1998 167 178
106. F. Madsen, K. Eberth, and J.D. Smart A rheological assessment of the nature of interactions between mucoadhesive polymers and homogenised mucus gel Biomaterials 19 1998 1083 1092
107. F.J. Holly Formation and rupture of the tear film Exp. Eye Res. 15 1973 515 525
108. A. Sharma, and E. Ruckenstein Mechanism of tear film rupture and formation of dry spots on cornea J. Colloid Interface Sci. 106 1985 12 27
109. H. Wong, I. Fatt, and C.J. Radke Deposition and thinning of the human tear film J. Colloid Interface Sci. 184 1996 44 51
110. M.S.R. Gorla, and R.S.R. Gorla Nonlinear theory of tear film rupture J. Biomec. Eng., Trans. ASME 122 2000 498 503
111. Y.L. Zhang, O.K. Matar, and R.V. Craster Analysis of tear film rupture: effect of non-Newtonian rheology J. Colloid Interface Sci. 262 2003 130 148
112. A. Sharma, and E. Ruckenstein The role of lipid abnormalities, aqueous and mucus deficiencies in the tear film breakup, and implications for tear substitutes and contact lens tolerance J. Colloid Interface Sci. 111 1986 8 34
113. M.S. Norn, and A. Opauszki Effects of ophthalmic vehicles on the stability of the precorneal tear film Acta Ophthalmol. (Copenh.) 55 1977 23 34
114. J.L. Greaves, O. Olejnik, and C.G. Wilson Polymers and the precorneal tear film S.T.P. Pharma Sci. 2 1992 13 33
115. J.H. Trueblood, R.M. Rossomondo, W.H. Carlton, and L.A. Wilson Corneal contact times of ophthalmic vehicles. Evaluation by microscintigraphy Arch. Ophthalmol. 93 1975 127 130
116. S.S. Chrai, and J.R. Robinson Ocular evaluation of methylcellulose vehicle in albino rabbits J. Pharm. Sci. 63 1974 1218 1223
117. T.F. Patton, and J.R. Robinson Ocular evaluation of polyvinylalcohol vehicle in rabbits J. Pharm. Sci. 65 1976 1295 1301
118. M.F. Saettone, B. Giannaccini, S. Ravecca, F. La Marca, and G. Tota Polymer effects on ocular bioavailability-the influence of different liquid vehicles on the mydriatic response of tropicamide in humans and rabbits Int. J. Pharm. 20 1984 187 202
119. M.F. Saettone, B. Giannaccini, A. Guiducci, F. Marca, and G. Tota Polymer effects on ocular bioavailability: II. The influence of benzalkonium chloride on the mydriatic response of tropicamide in different polymeric vehicles Int. J. Pharm. 25 1985 73 83
120. S.C. Chang, D.S. Chien, H. Bundgaard, and V.H.L. Lee Relative effectiveness of prodrug and viscous approaches in maximizing the ratio of ocular to systemic absorption of topically applied timolol Exp. Eye Res. 46 1988 56 69
121. G. Meseguer, R. Gurny, P. Buri, A. Rozier, and B. Plazonnet Gamma scintigraphic study of precorneal drainage and assessment of miotic response in rabbits of various ophthalmic formulations containing pilocarpine Int. J. Pharm. 95 1993 229 234
122. F. Thermes, A. Rozier, B. Plazonnet, and J. Grove Bioadhesion: the effect of polyacrylic acid on the ocular bioavailability of timolol Int. J. Pharm. 81 1992 59 65
123. A.J. Bron, H. Mangat, M. Quinlan, A. Foley-Nolan, P. Eustace, M. Fsadni, and P. Sunder Raj Polyacrylic acid gel in patients with dry eyes: a randomized comparison with polyvinyl alcohol Eur. J. Ophthalmol. 81 1998 81 89
124. O. Séchoy, G. Tissié, C. Sébastian, F. Maurin, J.-Y. Driot, and C. Trinquand A new long acting ophthalmic formulation of Carteolol containing alginic acid Int. J. Pharm. 207 2000 109 116
125. S. Burgalassi, P. Chetoni, and M.F. Saettone Hydrogels for ocular delivery of pilocarpine: preliminary evaluation in rabbits of the influence of viscosity and of drug solubility Eur. J. Pharm. 42 1996 385 392
126. C.-P. Lin, and M. Boehnke Influences of methylcellulose on corneal epithelial wound healing J. Ocul. Pharmacol. Ther. 15 1999 59 63
127. I. Toda, N. Shinozaki, and K. Tsubota Hydroxypropyl methylcellulose for the treatment of severe dry eye associated with Sjögren's syndrome Cornea 15 1996 120 128
128. D.A. Benedetto, D.O. Shah, and H.E. Kaufman The instilled fluid dynamics and surface chemistry of polymers in the precorneal tear film Invest. Ophthalmol. 14 1975 887 902
129. D.H. Donabedian, L. Martin, D.J. Eng, Compositions comprising cationic polysaccharides and cationic drugs. EP 0 888 770 A1 (1999).
130. W. Weyenberg, and A. Ludwig In vitro assessment of the interaction mechanism between mucin and cationic cellulosic derivatives by rheological methods using an experimental design Pharmazie 57 2002 628 631
131. S.S. Leung, and J.R. Robinson The contribution of anionic polymer structural features to mucoadhesion J. Control. Release 5 1988 223 231
132. Z. Degim, and I.W. Kellaway An investigation of the interfacial interaction between poly(acrylic acid) and glycoprotein Int. J. Pharm. 175 1998 9 16
133. V. Hartmann, and S. Keipert Physico-chemical, in vitro and in vivo characterisation of polymers for ocular use Pharmazie 55 2000 440 443
134. J. Ceulemans, and A. Ludwig Optimisation of carbomer viscous eye drops: an in vitro experimental design approach using rheological techniques Eur. J. Pharm. Biopharm. 54 2002 41 50
135. C.-M. Lehr, Y.-H. Lee, and V.H.L. Lee Improved ocular penetration of gentamicin by mucoadhesive polymer in the pigmented rabbit Invest. Ophthalmol. Visual Sci. 35 1994 2809 2814
136. M.F. Saettone, D. Monti, M.T. Torracca, P. Chetoni, and B. Giannaccini Mucoadhesive liquid ophthalmic vehicles: evaluation of macromolecular ionic complexes of pilocarpine Drug Dev. Ind. Pharm. 15 1989 2475 2489
137. H. Brewitt Tränenersatzmittel. Experimentelle und klinische Beobachtungen Klin. Mon.Bl. Augenheilkd. 193 1988 275 282
138. N. Unlü, A. Ludwig, M. Van Ooteghem, and A.A. Hincal A comparative rheological study on carbopol viscous solutions and, the evaluation of their suitability as the ophthalmic vehicles and artificial tears Pharm. Acta Helv. 67 1992 5 10
139. M. Oescher, and S. Keipert Polyacrylic acid/polyvinylpyrrolidone biopolymeric systems: I. Rheological and mucoadhesive properties of formulations potentially useful for the treatment of dry-eye-syndrome Eur. J. Pharm. Biopharm. 47 1999 113 118
140. K. Marner, P.M. Moller, M. Dillon, and E. Rask-Pedersen Viscous carbomer eye drops in patients with dry eye Acta Ophthalmol. Scand. 74 1996 249 252
141. K. Setiawan, N. Davies, I. Tucker, Patent WO98/47536.
142. T.C. Laurent Biochemistry of hyaluronan Acta Oto-Laryngol. (Stockh.), Suppl. 442 1987 7 24
143. Y.S. Wysenbeek, N. Loya, I. Ben Sira, I. Ophir, and Y. Ben Saul The effect of sodium hyaluronate on the corneal epithelium. An ultrastructural study Invest. Ophthalmol. Visual Sci. 29 1988 194 199
144. A. Ludwig, and M. Van Ooteghem Evaluation of sodium hyaluronate as viscous vehicle for eye drops J. Pharm. Belg. 44 1989 391 397
145. J.D. Nelson, and L. Farris Sodium hyaluranate and polyvinyl alcohol artificial tear preparation. A comparison in patients with keratoconjunctivitis sicca Arch. Ophthalmol. 106 1988 484 487
146. G.R. Snibson, J.L. Greaves, N.D.W. Soper, J.M. Tiffany, C.G. Wilson, and A.J. Bron Ocular surface residence time of artificial tear solutions Cornea 11 1992 288 293
147. S. Shimmura, M. Ono, K. Shinozaki, I. Toda, E. Takamura, Y. Mashima, and K. Tsubota Sodium hyaluronate eyedrops in the treatment of dry eyes Br. J. Ophthalmol. 79 1995 1007 1011
148. A. Solomon, and S. Merin The effect of a new tear substitute containing glycerol and hyaluronate on keratoconjunctivitis sicca J. Ocul. Pharmacol. Ther. 14 1998 497 504
149. P.I. Condon, C.G. McEwen, M. Wright, G. Mackintosh, R.J. Prescott, and C. McDonald Double blind, randomised, placebo controlled, crossover, multicenter study to determine the efficacy of a 0.1%(w/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome Br. J. Ophthalmol. 83 1999 1121 1124
150. P. Aragona, V. Papa, A. Micali, M. Santocono, and G. Milazzo Long term treatment of sodium-hyaluranate-containing artificial tears reduces ocular surface damage in patients with dry eye Br. J. Ophthalmol. 86 2002 181 184
151. R. Gurny, H. Ibrahim, A. Aebi, P. Buri, C.G. Wilson, N. Washington, P. Edman, and O. Camber Design and evaluation of controlled release systems for the eye J. Control. Release 6 1987 367 373
152. O. Camber, and P. Edman Sodium hyaluronate as an ophthalmic vehicle: some factors governing its effect on the ocular absorption of pilocarpine Curr. Eye Res. 6 1989 563 567
153. M.F. Saettone, B. Giannaccini, P. Chetoni, M.T. Torracca, and D. Monti Evaluation of high- and low-molecular-weight fractions of sodium hyaluronate and an ionic complex as adjuvants for topical ophthalmic vehicles containing pilocarpine Int. J. Pharm. 72 1991 131 139
154. A.M. Durrani, S.J. Farr, and I.W. Kellaway Influence of molecular weight and formulation pH on the precorneal clearance rate of hyaluronic acid in the rabbit eye Int. J. Pham. 118 1995 243 250
155. C. Bucolo, A. Spadaro, and S. Mangiafico Pharmacological evaluation of a new timolol/pilocarpine formulation Ophthalmic Res. 30 1998 101 108
156. R. Herrero-Vanrell, A. Fernandez-Carballido, G. Frutos, and R. Cadorniga Enhancement of the mydriatic response to tropicamide by bioadhesive polymers J. Ocul. Pharmacol. Ther. 16 2000 419 428
157. O. Camber, and P. Lundgren Diffusion of some low molecular weight compounds in sodium hyaluronate Acta Pharm. Suec. 22 1985 315 320
158. C. Bucolo, and P. Mangiafico Pharmacological profile of a new topical pilocarpine formulation J. Ocul. Pharmacol. Ther. 15 1999 567 573
159. G. Sandri, M.C. Bonferoni, S. Rossi, F. Ferrari, C. Ronchi, and C. Caramella Ophthalmic formulations based on ternary interaction systems drug-polymer-polymer Proceedings 30th Int. Symp. Control. Rel. Bioact. Mater. (Glasgow) 2003
160. C.M. Lehr, J.A. Bouwstra, E.H. Schacht, and H.E. Junginger In vitro evaluation of mucoadhesive properties of chitosan and other natural polymers Int. J. Pharm. 78 1992 43 48
161. E.E. Hassan, and J.M. Gallo A simple rheological method for the in vitro assessment of mucin-polymer bioadhesive bond strength Pharm. Res. 7 1990 491 495
162. O. Felt, P. Buri, and R. Gurny Chitosan: a unique polysaccharide for drug delivery Drug Dev. Ind. Pharm. 24 1998 979 993
163. O. Felt, P. Furrer, J.M. Mayer, B. Plazonnet, P. Buri, and R. Gurny Topical use of chitosan in ophthalmology: tolerance, assessment and evaluation of precorneal retention Int. J. Pharm. 180 1999 185 193
164. S. Rossi, F. Ferrari, M.C. Bonferoni, and C. Caramella Characterization of chitosan hydrochloride-mucin rheological interaction: influence of polymer concentration and polymer:mucin weight ratio Eur. J. Pharm. Sci. 12 2001 479 485
165. M.J. Alonso, and A. Sanchez The potential of chitosan in ocular drug delivery J. Pharm. Pharmacol. 55 2003 1451 1463
166. O. Felt, A. Carrel, P. Baehni, P. Buri, and R. Gurny Chitosan as tear substitute: a wetting agent endowed with antimicrobial efficacy J. Ocul. Pharmacol. Ther. 16 2000 261 270
167. P. Artursson, T. Lindmark, S.S. Davis, and L. Illum Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2) Pharm. Res. 11 1994 1358 1361
168. V. Dodane, M.A. Khan, and J.R. Mervin Effect of chitosan on epithelial permeability and structure Int. J. Pharm. 182 1999 21 32
169. N.G.M. Schipper, K.M. Varum, P. Stenberg, G. Ocklind, H. Lennernas, and P. Artursson Chitosans as absorption enhancers of poorly absorbable drugs: 3. Influence of mucus on absorption enhancement Eur. J. Pharm. Sci. 8 1999 335 343
170. M. Thanou, M.T. Nihot, M. Janssen, J.C. Verhoef, and H.E. Junginger Mono-N-carboxymethyl chitosan (MCC) a polyampholytic chitosan derivative, enhances the intestinal absorption of low molecular weight heparin across intestinal epithelia in vitro and in vivo J. Pharm. Sci. 90 2001 38 46
171. G. Di Colo, Y. Zambito, S. Burgalassi, and M.F. Saettone Effects of chitosan and of its N-trimethyl and N-carboxymethyl derivatives on the ocular pharmacokinetics of ofloxacin in rabbits Proceedings 30th Int. Symp. Control. Rel. Bioact. Mater. (Glasgow) 2003
172. M.F. Saettone, D. Monti, M.T. Torracca, and P. Chetoni Mucoadhesive ophthalmic vehicles: evaluation of polymeric low-viscosity formulations J. Ocul. Pharmacol. 10 1994 83 92
173. S. Burgalassi, P. Panichi, P. Chetoni, M.F. Saettone, and E. Boldrini Development of a simple dry eye model in the albino rabbit and evaluation of some tear substitutes Ophthalmic Res. 31 1999 229 235
174. M. Albasini, and A. Ludwig Evaluation of polysaccharides intended for ophthalmic use in ocular dosage forms Farmaco 50 1995 633 642
175. E. Verschueren, L. Van Santvliet, and A. Ludwig Evaluation of various carrageenans as ophthalmic viscolysers S.T.P. Pharma Sci. 6 1996 203 210
176. M.F. Saettone, D. Monti, B. Giannaccini, L. Salminen, and R. Huupponen Macromolecular ionic complexes of cyclopentolate for topical ocular administration. Preparation and preliminary evaluation in albino rabbits S.T.P. Pharma Sci. 2 1992 68 75
177. S. Burgalassi, P. Chetoni, L. Panichi, E. Boldrini, and M.F. Saettone Xyloglucan as a novel vehicle for timolol: pharmacokinetics and pressure lowering activity in rabbits J. Ocul. Pharmacol. Ther. 16 2000 497 509
178. L. Raimondi, L. Sgromo, G. Banchelli, I. Corti, R. Pirisino, and E. Boldrini A new viscosity enhancer for ophthalmic preparations devoid of toxicity for human conjunctival cells J. Toxicol., Cutan. Ocul. Toxicol. 19 2000 31 42
179. S. Burgalassi, L. Raimondi, R. Pirisino, G. Banchelli, E. Boldrini, and M.F. Saettone Effect of xyloglucan (tamarind seed polysaccharide) on conjunctival cell adhesion to laminin and on corneal epithelium wound healing Eur. J. Ophthalmol. 10 2000 71 76
180. M. D'Amico, C. Di Filippo, E. Lampa, E. Boldrini, F. Rossi, A. Ruggiero, and A. Filippelli Effects of timolol and timolol with tamarind seed polysaccharide on intraocular pressure in rabbits Pharm. Pharmacol. Commun. 5 1999 361 364
181. J. Ceulemans, I. Vinckier, and A. Ludwig The use of xanthan gum in an ophthalmic liquid dosage form: rheological characterization of the interaction with mucin J. Pharm. Sci. 91 2002 1117 1127
182. G. Meseguer, P. Buri, B. Plazonnet, A. Rozier, and R. Gurny Gamma scintigraphic comparison of eyedrops containing pilocarpine in healthy volunteers J. Ocul. Pharmacol. Ther. 12 1996 481 488
183. A. Bernkop-Schnuerch, Mucoadhesive polymers, use thereof and method for producing the same. Patent EP 1126881 (1998).
184. A. Bernkop-Schnuerch, U.-M. Brandt, and A. Clausen Synthese und in vitro Evaluiering von Chitosan-Cystein Konjugaten Sci. Pharm. 67 1999 197 208
185. A. Bernkop-Schnuerch, V. Schwarz, and S. Steininger Polymers with thiol groups: a new generation of mucoadhesive polymers? Pharm. Res. 16 1999 876 881
186. A. Bernkop-Schnuerch, and S. Steininger Synthesis and characterisation of mucoadhesive thiolated polymers Int. J. Pharm. 194 2000 239 247
187. A. Bernkop-Schnuerch, S. Scholler, and R.G. Biebel Development of controlled release systems based on thiolated polymers J. Control. Release 66 2000 39 48
188. A. Bernkop-Schnuerch Mucoadhesive polymers S. Dimitriu Polymeric Biomaterials 2000 Marcel Dekker, Inc. New York 147 165
189. A. Bernkop-Schnuerch, C.E. Kast, and M.F. Richter Improvement in the mucoadhesion properties of alginate by the covalent attachment of cysteine J. Control. Release 71 2001 277 285
190. C.E. Kast, and A. Bernkop-Schnuerch Thiolated polymers-thiomers: development and in vitro evaluation of chitosan-thioglycoloc acid conjugates Biomaterials 22 2001 2345 2352
191. A.H. Krauland, V.M. Leitner, and A. Bernkop-Schnuerch Improvement in the in situ gelling properties of deacetylated gellan gum by the immobilization of
192. V.M. Leitner, G.F. Walker, and A. Bernkop-Schnuerch Thiolated polymers: evidence for the formation of disulphide bonds with mucus glycoproteins Eur. J. Pharm. Biopharm. 56 2003 207 214
193. M.K. Marschütz, and A. Bernkop-Schnuerch Thiolated polymers: self-crosslinking properties of thiolated 450 kDA poly(acrylic acid) and their influence on mucoadhesion Eur. J. Pharm. Sci. 15 2002 387 394
194. A.E. Clausen, and A. Bernkop-Schnuerch In vitro evaluation of the permeation-enhancing effect of thiolated polycarbophil J. Pharm. Sci. 89 2000 1253 1261
195. A. Bernkop-Schnuerch, C.E. Kast, and D. Guggi Permeation enhancing polymers in oral delivery of hydrophilic macromolecules: thiomer/GSH systems J. Control. Release 93 2003 95 103
196. A.E. Clausen, C.E. Kast, and A. Bernkop-Schnuerch The role of glutathione in the permeation enhancing effect of thiolated polymers Pharm. Res. 19 2002 602 608
197. M.D. Hornof, and A. Bernkop-Schnuerch In vitro evaluation of the permeation enhancing effect of polycarbophil-cysteine conjugates on the cornea of rabbits J. Pharm. Sci. 91 2002 2588 2592
198. V.M. Leitner, M.K. Marschütz, and A. Bernkop-Schnuerch Mucoadhesive and cohesive properties of poly(acrylic acid)-cysteine conjugates with regard to their molecular mass Eur. J. Pharm. 18 2003 89 96
199. A.J. Augustin, M. Spitznas, N. Kaviani, D. Meller, F.H. Koch, F. Grus, and M.J. Gobbels Oxidative reactions in the tear film of patients suffering from dry eyes Graefe Arch. Clin. Exp. Ophthalmol. 233 1995 694 698
200. D. Meisner, and M. Mezei Liposome ocular systems Adv. Drug Deliv. Rev. 16 1995 75 93
201. M.S. Nagarsenker, V.Y. Londhe, and G.D. Nadkarni Preparation of liposomal formulation of tropicamide for ocular delivery Int. J. Pharm. 190 1999 63 71
202. O.N. El-Gazayerly, and A.H. Hikal Preparation and evaluation of acetazolamide liposomes as an ocular delivery system Int. J. Pharm. 158 1997 121 127
203. S. Ding Recent developments in ophthalmic drug delivery Pharm. Sci. Technol. Today 1 1998 328 335
204. M. Fresta, A.M. Panico, C. Bucolo, C. Giannavola, and G. Puglisi Characterization and in-vivo ocular absorption of liposome-encapsulated acyclovir J. Pharm. Pharmacol. 51 1999 565 576
205. S.L. Law, K.J. Huang, and C.H. Chiang Acyclovir-containing liposomes for potential ocular delivery. Corneal penetration and absorption J. Control. Release 63 2000 135 140
206. H.-H. Lin, S.-M. Ko, L.-R. Hsu, and Y.-H. Tsai The preparation of norfloxacin-loaded liposomes and their in-vitro evaluation in pig's eye J. Pharm. Pharmacol. 48 1996 801 805
207. N.M. Davies, S.J. Farr, J. Hadgraft, and I.W. Kellaway Evaluation of mucoadhesive polymers in ocular drug delivery: II. Polymer-coated vesicles Pharm. Res. 9 1992 1137 1144
208. A.M. Durrani, N.M. Davies, M. Thomas, and I.W. Kellaway Pilocarpine bioavailability from mucoadhesive liposomal drug delivery system Int. J. Pharm. 88 1992 409 415
209. H.E. Schaeffer, J.M. Briefeller, and D.L. Krohn Lectin-mediated attachment of liposome to cornea: influence on transcorneal drug flux Invest. Ophthalmol. 23 1983 530 533
210. T.J. Nicholls, K.L. Green, D.J. Rogers, J.D. Cook, S. Wolowacz, and J.D. Smart Lectins in ocular drug delivery: an investigation of lectin binding sites on the corneal and conjunctival surfaces Int. J. Pharm. 138 1996 175 183
211. T.J. Nicholls, D.J. Cook, D.J. Rogers, K.L. Green, and J.D. Smart Lectins in ocular drug delivery-an in-vivo study of lectin retention on ocular surfaces Pharm. Sci. 3 1997 77 81
212. C.-M. Lehr Lectin-mediated drug delivery: the second generation of bioadhesives J. Control. Release 65 2000 19 29
213. F. Gabor, and M. Wirth Lectin-mediated drug delivery: fundamentals and perspectives S.T.P. Pharma Sci. 13 2003 3 16
214. I. Henriksen, K.L. Green, J.D. Smart, G. Smistad, and J. Karlsen Bioadhesion of hydrated chitosans: an in vitro and in vivo study Int. J. Pharm. 145 1996 231 240
215. A. Bochot, E. Fattal, A. Gulik, G. Couarraze, and P. Couvreur Liposomes dispersed within a thermosensitive gel: a new dosage form for ocular delivery of oligonucleotides Pharm. Res. 15 1998 1364 1369
216. A. Bochot, E. Fattal, J.L. Grossiord, F. Puisieux, and P. Couvreur Characterization of a new drug delivery system based on dispersion of liposomes in a thermosensitive gel Int. J. Pharm. 162 1998 119 127
217. A. Bochot, B. Mashhour, F. Puisieux, P. Couvreur, and E. Fattal Comparison of the ocular distribution of a model oligonucleotide after topical instillation in rabbits of conventional and new dosage forms J. Drug Target. 6 1998 309 313
218. J. Kreuter Particulates (nanoparticles and microparticles) A.K. Mitra Ophthalmic Drug Delivery Systems 1993 Marcel Deker New York 275 297
219. A. Zimmer, and J. Kreuter Microspheres and nanoparticles used in ocular delivery systems Adv. Drug Deliv. Rev. 16 1995 61 73
220. A. Joshi Microparticulates for ophthalmic drug delivery J. Ocul. Pharmacol. 10 1994 29 45
221. N. Faisant, J. Siepmann, and J.P. Benoit PLGA-based microparticles: elucidation of mechanisms and a new, simple mathematical model quantifying drug release Eur. J. Pharm. Sci. 15 2002 355 366
222. H.Z. Klein, M. Lugo, B. Shields, J. Leon, and E. Duzman A dose-reponse study of Piloplex for duration of action Am. J. Ophthalmol. 99 1985 23 26
223. A.M. Durrani, S.J. Farr, and I.W. Kellaway Precorneal clearance of mucoadhesive microspheres from the rabbit eye J. Pharm. Pharmacol. 47 1995 581 584
224. T. Inoue, G. Chen, K. Nakamae, and A.S. Hoffman An AB block copolymer of oligo(methyl methacrylate) and poly(acrylic acid) for micellar delivery of hydrophobic drugs J. Control. Release 51 1998 221 229
225. 14C] acrylate nanoparticles in healthy and chronically inflamed rabbit eyes Int. J. Pharm. 54 1989 149 153
226. K. Langer, A. Zimmer, and J. Kreuter Acrylic nanoparticles for ocular drug delivery S.T.P. Pharma Sci. 7 1997 445 451
227. S.D. Desai, and J. Blanchard Pluronic F127-based ocular delivery systems containing biodegradable polyisobutylcyanoacrylate nanocapsules of pilocarpine J. Drug. Deliv. Target. Ther. Agents 7 2000 201 207
228. M. Fresta, G. Fontana, C. Bucolo, G. Cavallaro, G. Giammona, and G. Puglisi Ocular tolerability and in vivo bioavailability of poly(ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanospheres-encapsulated acyclovir J. Pharm. Sci. 90 2001 288 297
229. A. Zimmer, J. Kreuter, and J.R. Robinson Studies on the transport pathway of PBCA nanoparticles in ocular tissues J. Microencapsul 8 1991 497 504
230. C.A. Le Bourlais, F. Chevanne, B. Turlin, L. Acar, H. Zia, P.A. Sado, T.E. Needham, and R. Leverge Effect of cyclosporine A formulations on bovine corneal absorption: ex vivo study J. Microencapsul 14 1997 457 467
231. K. Langer, F. Stieneker, G. Lambrecht, E. Mutschler, and J. Kreuter Methylmethacrylate sulfopropyl methacrylate copolymer nanoparticles for drug delivery: Part II. Arecaidine propargyl ester and pilocarpine loading and in vitro release Int. J. Pharm. 158 1997 211 217
232. K. Langer, E. Mutschler, G. Lambrecht, D. Mayer, G. Troschau, F. Stieneker, and J. Kreuter Methylmethacrylate sulfopropylmethacrylate copolymer nanoparticles for drug delivery: Part III. Evaluation as drug delivery system for ophthalmic applications Int. J. Pharm. 158 1997 219 231
233. R. Pignatello, C. Bucolo, and G. Puglisi Ocular tolerability of Eudragit RS 100® and RL 100® nanosuspensions as carriers for ophthalmic controlled drug delivery J. Pharm. Sci. 91 2002 2636 2641
234. R. Pignatello, C. Bucolo, P. Ferrara, A. Maltese, A. Puleo, and G. Puglisi Eudragit RS 100® nanosuspensions for ophthalmic controlled delivery of ibuprofen Eur. J. Pharm. 16 2002 53 61
235. R. Pignatello, C. Bucolo, G. Spedalieri, A. Maltese, and G. Puglisi Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application Biomaterials 23 2002 3247 3255
236. C. Bucolo, A. Maltese, G. Puglisi, and R. Pignatello Enhanced ocular anti-inflammatory activity of ibuprofen carried by Eudragit RS 100® nanoparticulate suspension Ophthalmic Res. 34 2002 319 323
237. S.M. Safwat, and R.S. Al-Kassas Evaluation of gentamicin-Eudragit microspheres as ophthalmic delivery systems in inflamed rabbit's eyes S.T.P. Pharma Sci. 12 2002 357 361
238. A.K. Gupta, S. Madan, D.K. Majumdar, and A. Maitra Ketorolac entrapped in polymeric micelles: preparation, characterisation and ocular anti-inflammatory studies Int. J. Pharm. 209 2000 1 14
239. G.-H. Hsiue, S.-H. Hsu, C.-C. Yang, S.-H. Lee, and I.-K. Yang Preparation of controlled release ophthalmic drops, for glaucoma therapy using thermosensitive poly-N-isopropylacrylamid Biomaterials 23 2002 457 462
240. A.A. Deshpande, J. Heller, and R. Gurny Bioerodible polymers for ocular delivery Crit. Rev. Ther. Drug Carr. Syst. 15 1998 381 420
241. L. Marchal-Heussler, H. Fessi, J.P. Devissaguet, M. Hoffman, and P. Maincent Colloidal drug delivery systems for the eye: a comparison of the efficacy of three different polymers: polyisobutylcyanoacrylate, poly(lactic-co-glycolic acid), poly(epsilon-caprolactone) S.T.P. Pharma Sci. 2 1992 98 104
242. P. Calvo, J.L. Vila-Jato, and M.J. Alonso Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers Int. J. Pharm. 153 1997 41 50
243. P. Calvo, J.L. Vila-Jato, and M.J. Alonso Effect of lysozyme on the stability of polyester nanocapsules and nanoparticles: stabilization approaches Biomaterials 18 1997 1305 1310
244. S. Barbault-Foucher, R. Gref, P. Russo, J. Guechot, and A. Bochot Design of poly-epsilon-caprolactone nanospheres coated with bioadhesive hyaluronic acid for ocular delivery J. Control. Release 83 2002 365 375
245. A.M. De Campos, A. Sanchez, R. Gref, P. Calvo, and M.J. Alonso The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa Eur. J. Pharm. Sci. 20 2003 73 81
246. H. Kimura, and Y. Ogura Biodegradable polymers for ocular drug delivery Ophthalmologica 215 2001 143 155
247. T.L. Ke, G. Cagle, B. Schlech, O.J. Lorenzetti, and J. Mattern Ocular bioavailability of ciprofloxacin in sustained release formulations J. Ocul. Pharmacol. Ther. 17 2001 555 563
248. C. Giannavola, C. Bucolo, A. Maltese, D. Paolino, M.A. Vandelli, G. Puglisi, V.H.L. Lee, and M. Fresta Influence of preparations on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability Pharm. Res. 20 2003 584 590
249. L. Nobs, F. Buchegger, R. Gurny, and A. Alléman Surface modification of poly(lactic acid) nanoparticles by covalent attachment of thiol groups by means of three methods Int. J. Pharm. 250 2003 327 337
250. K. Kyyrönen, L. Hume, L. Benedetti, A. Urtti, E. Topp, and V. Stella Methylprednisolone esters of hyaluronic acid in ophthalmic drug delivery: in vitro and in vivo release Int. J. Pharm. 80 1992 161 169
251. I. Genta, B. Conti, P. Prugini, F. Pavanetto, A. Spadaro, and P. Puglisi Bioadhesive microspheres for ophthalmic administration of acyclovir J. Pharm. Pharmacol. 49 1997 737 742
252. F. Ferrari, S. Rossi, M. Bonferoni, C. Caramella, and J. Karlsen Characterisation of rheological and mucoadhesive properties of three grades of chitosan hydrochloride Farmaco 52 1997 493 497
253. S. Kas Chitosan: properties, preparations and applications to microparticulate systems J. Microencapsul 14 1997 689 742
254. A.M. De Campos, A. Sanchez, and M.J. Alonso Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A Int. J. Pharm. 224 2001 159 168
255. P. Giunchedi, U. Conte, P. Chetoni, and M.F. Saettone Pectin microspheres as ophthalmic carriers for piroxicam: evaluation in vitro and in vivo in albino rabbits Eur. J. Pharm. Sci. 9 1999 1 7
256. S. Leucuta The kinetics of in vitro release and the pharmacokinetics of miotic response in rabbits of gelatin and albumin microspheres with pilocarpine Int. J. Pharm. 54 1989 71 78
257. P. Giunchedi, P. Chetoni, U. Conte, and M.F. Saettone Albumin microspheres for ocular delivery of piroxicam Pharm. Pharmacol. Commun. 6 2000 149 153
258. A. Zimmer, P. Maincent, P. Thouvenot, and J. Kreuter Hydrocortisone delivery to healthy and inflamed eyes using a micellar polysorbate 80 solution or albumin nanoparticles Int. J. Pharm. 110 1994 211 222
259. A.K. Zimmer, P. Chetoni, M.F. Saettone, H. Zerbe, and J. Kreuter Evaluation of pilocarpine-loaded albumin particles as controlled drug delivery systems for the eye: II. Co-administration with bioadhesive and viscous polymers J. Control. Release 33 1995 31 46
260. R. Cavalli, M.R. Gasco, P. Chetoni, S. Burgalassi, and M.F. Saettone Solid lipid nanoparticles (SLN) as ocular delivery systems for tobramycin Int. J. Pharm. 238 2002 241 245
261. M. Zignani, C. Tabatabay, and R. Gurny Topical semi-solid drug delivery: kinetics and tolerance of ophthalmic hydrogels Adv. Drug Deliv. Rev. 16 1995 51 69
262. B.S. Lele, and A.S. Hoffman Mucoadhesive drug carriers based on complexes of poly(acrylic acid) and PEGylated drugs having hydrolysable PEG-anhydride-drug linkages J. Control. Release 69 2000 237 248
263. M. Paulsson, and K. Edsman Controlled drug release from gels using surfactant aggregates: 1. Effect of lipophilic interactions for a series of uncharged substances J. Pharm. Sci. 90 2001 1216 1225
264. M. Paulsson, and K. Edsman Controlled drug release from gels using lipophilic interactions of charged substances with surfactants and polymers J. Colloid Interface Sci. 248 2002 194 200
265. M.C. Bonferoni, E. Gavini, G. Sandri, F. Ferrari, S. Rossi, and C. Caramella Ciprofloxacin-polymer coprecipitates for ophthalmic application Proceedings 30th Int. Symp. Control. Rel. Bioact. Mater. (Glasgow) 2003
266. K. Lindell, and S. Engström In vitro release of timolol maleate from an in situ gelling polymer system Int. J. Pharm. 95 1993 219 228
267. S. Tamburic, and D.Q.M. Craig An investigation into the rheological, dielectric and mucoadhesive properties of poly(acrylic acid) gel systems J. Control. Release 37 1995 59 68
268. K. Edsman, J. Carlfors, and K. Harju Rheological evaluation and ocular contact time of some carbomer gels for ophthalmic use Int. J. Pharm. 137 1996 233 241
269. C.G. Wilson, Y.P. Zhu, M. Frier, L.S. Rao, P. Gilchrist, and A.C. Perkins Ocular contact time of a carbomer gel (GelTears) in humans Br. J. Ophthalmol. 82 1998 1131 1134
270. D.L. Middleton, and J.R. Robinson Design and evaluation of an ocular bioadhesive delivery system S.T.P. Pharma Sci. 1 1991 200 206
271. S. Kumar, and K.J. Himmelstein Modification of in situ gelling behaviour of carbopol solutions by hydroxypropyl methylcellulose J. Pharm. Sci. 84 1995 344 348
272. B. Srividya, R.M. Cardoza, and P.D. Amin Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system J. Control. Release 73 2001 205 211
273. L.J. Sullivan, F. McCurrach, S. Lee, H.R. Taylor, M. Rolando, C. Marechal-Courtois, C. Creuzot-Garcher, D.L. Easty, C. Karabatsas, M.B. Hoh, C. Faschinger, and L. Laroche Efficacy and safety of 0.3% carbomer gel compared to placebo in patients with moderate-to-severe dry eye syndrome Ophthalmology 104 1997 1402 1408
274. H.G. Struck, and A. Bariszlovich Comparison of 0.1% dexamethasone phosphate eye gel (Dexagel) and 1% prednisolone acetate eye suspension in the treatment of post-operative inflammation after cataract surgery Graefe Arch. Clin. Exp. Ophthalmol. 239 2001 737 742
275. D.L. Meadows, J.R. Paugh, A. Joshi, and J. Mordaunt A novel method to evaluate residence time in humans using a nonpenetrating fluorescent tracer Invest. Ophthalmol. Visual Sci. 43 2002 1032 1039
276. J.J. Sahlin, and N.A. Peppas Enhanced hydrogel adhesion by polymer interdiffusion: use of linear poly(ethylene glycol) as an adhesion promoter J. Biomater. Sci., Polym. Ed. 8 1997 421 436
277. P. Bures, Y. Huang, E. Oral, and N.A. Peppas Surface modifications and molecular imprinting of polymers in medical and pharmaceutical applications J. Control. Release 72 2001 25 33
278. C. Debbasch, P.-J. Pisella, P. Rat, J.-M. Warnet, and C. Baudouin Evaluation de la cytotoxicité de trois substituts lacrymaux utilisés dans le traitement des syndromes secs J. Fr. Ophtalmol. 23 2000 863 869
279. C. Debbasch, S. Bruneau De la Salle, F. Brignole, P. Rat, J.-M. Warnet, and C. BaudouinCytoprotective effects of hyaluronic acid and carbomer 934P in ocular surface epithelial cells Invest. Ophthalmol. Visual Sci. 43 2002 3409 3415
280. J. Li, and Z. Xu Physical characterisation of a chitosan-based hydrogel delivery system J. Pharm. Sci. 91 2002 1669 1677
281. V. Hartmann, and S. Keipert Influence of divalent cations on deacetylated gellan and pilocarpine containing ophthalmic preparations Pharm. Pharmacol. Lett. 6 1996 98 101
282. M. Paulsson, H. Hägerström, and K. Edsman Rheological studies of the gelation of deacetylated gellan gum (Gelrite®) in physiological conditions Eur. J. Pharm. Sci. 9 1999 99 105
283. A. Rozier, C. Mazuel, J. Grove, and B. Plazonnet Functionality testing of gellan gum, a polymeric excipient material for ophthalmic dosage form Int. J. Pharm. 153 1997 191 198
284. H.I. Schenker, and L.H. Silver Long-term intraocular pressure-lowering efficacy and safety of timolol maleate gel-forming solution 0.5% compared with Timoptic XE 0.5% in a 12-month study Am. J. Ophthalmol. 130 2000 145 150
285. Y.D. Sanzgiri, S. Maschi, V. Crescenzi, L. Callegaro, E.M. Topp, and V.J. Stella Gellan-based systems for ophthalmic sustained delivery of methylprednisolone J. Control. Release 26 1993 195 201
286. D.M. Maurice, and S.P. Srinivas Use of fluorometry in assessing the efficacy of a cationic-sensitive gel as an ophthalmic vehicle: comparison with scintigraphy J. Pharm. Sci. 81 1992 615 619
287. J. Carlfors, K. Edsman, R. Petersson, and K. Jörnving Rheological evaluation of Gelrite® in situ gels for ophthalmic use Eur. J. Pharm. Sci. 6 1998 113 119
288. K. Edsman, J. Carlfors, and R. Petersson Rheological evaluation of poloxamer as an in situ gel for ophthalmic use Eur. J. Pharm. Sci. 6 1998 105 112
289. A.-C. Albertsson, J. Carlfors, and C. Sturesson Preparation and characterisation of poly(adipic anhydride) microspheres for ocular drug delivery J. Appl. Polym. Sci. 62 1996 695 705
290. A. Shedden, J. Laurence, and R. Tipping Efficacy and tolerability of timolol maleate gel-forming solution in adults with open-angle glaucoma or ocular hypertension: a six month double masked multicenter study Clin. Ther. 23 2001 440 450
291. W.C. Stewart, T.M. Leland, E.A. Cate, and J.A. Stewart Efficacy and safety of timolol solution once daily versus timolol gel in treating elevated intraocular pressure J. Glaucoma 7 1998 402 407
292. E.F. Rosenlund The intraocular pressure-lowering effect of timolol in gel-forming solution Acta Ophthalmol. Scand. 74 1996 160 162
293. P. Furrer, J. Berger, J.M. Mayer, and R. Gurny Etude comparative de la tolérance oculaire de 3 spécialités à base de timolol: influence du conservateur sur la tolérance oculaire J. Fr. Ophtalmol. 24 2001 13 19
294. T. Shibuya, K. Kashiwagi, and S. Tsukahara Comparison of efficacy and tolerability between two gel-forming timolol maleate ophthalmic solutions in patients with glaucoma or ocular hypertension Ophthalmologica 217 2003 31 38
295. C.B. Camras, C.B. Toris, and R.R. Tamesis Efficacy and adverse effects of medications used in treatment of glaucoma Drugs Aging 15 1999 377 388
296. S. Cohen, E. Lobel, A. Trevgoda, and Y. Peled A novel in-situ forming ophthalmic drug delivery system from alginates undergoing gelation in the eye J. Control. Release 44 1997 201 208
297. P. Demailly, C. Allaire, and C. Trinquand Ocular hypotensive efficacy and safety of once daily carteolol alginate Br. J. Ophthalmol. 85 2001 921 924
298. C. Trinquand, J.-P. Romanet, J.-P. Nordmann, and C. Allaire Efficacité et tolérance du cartéolol 1% à libération prolongée une fois par jour J. Fr. Ophtalmol. 26 2003 131 136
299. C. Baudouin, A. Béchetoille, A. Bron, P. Denis, J.-P. Nordmann, J.-P. Renard, J.-F. Rouland, E. Sellem, M.-C. Rigeade, and B. Arnould Intérêt de la mesure de la qualité de vie (QDV) et de l'observance thérapeutique chez les patients atteints de glaucoma chronique à angle ouvert J. Fr. Ophtalmol. 23 2000 1057 1064
300. C. Koller, and P. Buri Propriétés et intérêt pharmaceutique des gels thermoréversibles à base de poloxamers et poloxamines S.T.P. Pharma 3 1987 115 124
301. M.F. Saettone, B. Giannaccini, G. Delmonte, V. Campigli, G. Tota, and F. La Marca Solubilization of tropicamide by poloxamers: physicochemical data and activity data in rabbits and humans Int. J. Pharm. 43 1988 67 76
302. P. Chetoni, L. Panichi, S. Burgalassi, U. Benelli, and M.F. Saettone Pharmacokinetics and anti-inflammatory activity in rabbits of a novel indomethacin ophthalmic solution J. Ocular Pharmacol. Ther. 16 2000 363 372
303. J. Liaw, S.-F. Chang, and F.-C. Hsiao In vivo gene delivery into ocular tissues by eye drops of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) polymeric micelles Gene Ther. 8 2001 999 1004
304. P. Furrer, B. Plazonnet, J.M. Mayer, and R. Gurny Application of in vivo confocal microscopy to the objective evaluation of ocular irritation induced by surfactants Int. J. Pharm. 207 2000 89 98
305. E.-Y. Kim, Z.-G. Gao, J.-S. Park, H. Li, and K. Han rhEGF/HP-beta-CD complex in poloxamer gel for ophthalmic delivery Int. J. Pharm. 233 2002 159 167
306. S.D. Desai, and J. Blanchard Evaluation of Pluronic F 127-based sustained-release ocular delivery systems for pilocarpine using the albino rabbit eye model J. Pharm. Sci. 87 1998 1190 1195
307. S. Miyazaki, S. Suzuki, N. Kawasaki, K. Endo, A. Takahashi, and D. Attwood In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride Int. J. Pharm. 229 2001 29 36
308. H.-R. Lin, and K.C. Sung Carbopol/pluronic phase change solutions for ophthalmic drug delivery J. Control. Release 69 2000 379 388
309. G. Wei, H. Xu, P.T. Ding, S.M. Li, and J.M. Zheng Thermosetting gels with modulated gelation temperature for ophthalmic use: the rheological and gamma scintigraphic studies J. Control. Release 83 2002 65 74
310. A.H. El-Kamel In vitro and in vivo evaluation of Pluronic F127-based ocular delivery systems for timolol maleate Int. J. Pharm. 241 2002 47 55
311. K.Y. Cho, T.W. Chung, B.C. Kim, M.K. Kim, J.H. Lee, W.R. Wee, and C.S. Cho Release of ciprofloxacin from poloxamer-graft-hyaluronic acid hydrogels in vitro Int. J. Pharm. 260 2003 83 91
312. D.M. Worthen, T.J. Zimmer, and C.A. Wind Evaluation of pilocarpine Ocusert Invest. Ophthalmol. Visual Sci. 13 1974 296 299
313. G.L. Khromow, A.B. Davydov, A.B. Maychuk, I.F. Tishina, Base for ophthalmic medicinal preparations and an ophthalmological medicinal film US patent 3,935, 303 (1976).
314. J.W. Shell Ophthalmic drug delivery systems Surv. Ophthalmol. 29 1984 117 128
315. M.F. Saettone, and L. Salminen Ocular inserts for topical delivery Adv. Drug Deliv. Rev. 16 1995 95 106
316. F. Gurtler, and R. Gurny Patent literature review of ophthalmic inserts Drug Dev. Ind. Pharm. 21 1995 1 18
317. S.A. Mortazavi, and J.D. Smart An investigation into the role of water movement and mucus gel dehydration in mucoadhesion J. Control. Release 25 1993 197 203
318. M.J. Tobyn, J.R. Johnson, and P.W. Dettmar Factors affecting in vitro gastric mucoadhesion: III. Influence of polymer addition on the observed mucoadhesion of some materials Eur. J. Pharm. Biopharm. 42 1996 331 335
319. P. Chetoni, L. Mariotti Bianchi, B. Giannaccini, M.F. Saettone, U. Conte, and M.E. Sangalli Ocular mini-tablets for controlled release of timolol: evaluation in rabbits J. Ocul. Pharmacol. Ther. 12 1996 245 252
320. V. Baeyens, C. Percicot, M. Zignani, A.A. Deshpande, V. Kaltsatos, and R. Gurny Ocular drug delivery in veterinary medicine Adv. Drug Deliv. Rev. 28 1997 335 361
321. M. Kuwano, Y. Horibe, and Y. Kawashima Effect of collagen corneal shields in ocular drug delivery J. Ocul. Pharmacol. Ther. 13 1997 31 40
322. Y.-C. Lee, J.W. Millard, G.J. Negvesky, S.I. Butrus, and S.H. Yalkowsky Formulation and in vivo evaluation of ocular insert containing phenylephrine and tropicamide Int. J. Pharm. 182 1999 121 126
323. J.-M. Aiache, S. El Meski, G. Serpin, E. Beyssac, and R. Conti Local tolerance and in vivo release study of a new ocular drug delivery system DDS & S 1 2001 85 87
324. S. Kawakami, K. Nishida, T. Mukai, K. Yamamura, J. Nakamura, T. Sakaeda, M. Nakashima, and H. Sasaki Controlled release and ocular absorption of tilisolol utilizing ophthalmic insert-incorporated lipophilic prodrugs J. Control. Release 76 2001 255 263
325. H. Sasaki, T. Nagano, K. Sakanaka, S. Kawakami, K. Nishida, J. Nakamura, N. Ichikawa, J. Iwashita, T. Nakamura, and M. Nakashima One-side coated insert as unique ophthalmic drug delivery system J. Control. Release 92 2003 241 247
326. N.A. Charoo, K. Kohli, A. Ali, and A. Anwer Ophthalmic delivery of ciprofloxacin hydrochloride from different polymer formulations: in vitro and in vivo studies Drug Dev. Ind. Pharm. 29 2003 215 221
327. A. Karatas, and T. Baykara Studies of indomethacin inserts prepared using water-soluble polymers: I. Effect of the preparation method and polymers on drug release S.T.P. Pharma Sci. 10 2000 187 193
328. A. Lux, S. Maier, S. Dinslage, R. Süverkrüp, and M. Diestelhorst A comparative bioavailability study of three conventional eye drops versus a single lyophilisate Br. J. Ophthalmol. 87 2003 436 440
329. F. Gurtler, V. Kaltsatos, B. Boisramé, and R. Gurny Long-acting soluble bioadhesive ophthalmic drug insert (BODI) containing gentamicin for veterinary use: optimization and clinical investigation J. Control. Release 33 1995 231 236
330. F. Gurtler, V. Kaltsatos, B. Boisramé, J. Deleforge, M. Gex-Fabry, L.P. Balant, and R. Gurny Ocular availability of gentamicin in small animals after topical administration of a conventional eye drop solution and a novel long acting bioadhesive ophthalmic drug insert Pharm. Res. 12 1995 1791 1795
331. V. Baeyens, V. Kaltsatos, B. Boisramé, M. Fathi, and R. Gurny Evaluation of soluble bioadhesive ophthalmic drug inserts (BODI®) for prolonged release of gentamicin: lachrymal pharmacokinetics and ocular tolerance J. Ocul. Pharmacol. Ther. 14 1998 263 272
332. V. Baeyens, O. Felt-Baeyens, S. Rougier, S. Pheulpin, B. Boisramé, and R. Gurny Clinical evaluation of bioadhesive ophthalmic drug inserts (BODI®) for the treatment of external ocular infections in dogs J. Control. Release 85 2002 163 168
333. V. Baeyens, V. Kaltsatos, B. Boisramé, E. Varesio, J.-L. Veuthey, M. Fathi, L.P. Balant, M. Gex-Fabry, and R. Gurny Optimized release of dexamethasone and gentamicin from soluble ocular insert for the treatment of external ophthalmic solutions J. Control. Release 52 1998 215 220
334. P. Chetoni, G. Di Colo, M. Grandi, M. Morelli, M.F. Saettone, and S. Darougar Silicone rubber/hydrogel composite ophthalmic inserts: preparation and preliminary in vitro/in vivo evaluation Eur. J. Pharm. Biopharm. 46 1998 125 132
335. J. Ceulemans, A. Vermeire, E. Adriaens, J.P. Remon, and A. Ludwig Evaluation of a mucoadhesive tablet for ocular use J. Control. Release 77 2001 333 344
336. W. Weyenberg, A. Vermeire, J.P. Remon, and A. Ludwig Characterization and in vivo evaluation of ocular bioadhesive minitablets compressed at different forces J. Control. Release 89 2003 329 340
337. G. Di Colo, S. Burgalassi, P. Chetoni, M.P. Fiaschi, Y. Zambito, and M.F. Saettone Gel-forming erodible inserts for controlled delivery of ofloxacin Int. J. Pharm. 215 2001 101 111
338. G. Di Colo, S. Burgalassi, P. Chetoni, M.P. Fiaschi, Y. Zambito, and M.F. Saettone Relevance of polymer molecular weight to the in vitro/in vivo performance of ocular inserts based on poly(ethylene oxide) Int. J. Pharm. 220 2001 169 177
339. G. Di Colo, Y. Zambito, S. Burgalassi, A. Serafini, and M.F. Saettone Effect of chitosan on in vitro release and ocular delivery of ofloxacin from erodible inserts based on poly(ethylene oxide) Int. J. Pharm. 248 2002 115 122
340. G. Di Colo, and Y. Zambito A study of release mechanisms of different ophthalmic drugs from erodible ocular inserts based on poly(ethylene oxide) Eur. J. Pharm. Sci. 54 2002 193 199
341. M. Hornhof, W. Weyenberg, A. Ludwig, and A. Bernkop-Schnuerch Mucoadhesive ocular insert based on thiolated poly(acrylic acid): development and in vivo evaluation in humans J. Control. Release 89 2003 419 428